 Veru ought to find out very soon whether its lead asset, Sabizabulin, has been awarded an Emergency Use Authorization to treat hospitalized COVID patients. The companys share price leapt 20 when its COVID study data was published, showing a clinically and statistically meaningful 55 relative reduction in deaths. 